Recent progress in the discovery of macrocyclic compounds as potential anti-infective therapeutics

Current Medicinal Chemistry

Volumn 16, Issue 1, 2009, Pages 42-65

  Obrecht, Daniel ^a   Robinson, J A ^b   Bernardini, F ^a   Bisang, C ^a   DeMarco, S J ^a   Moehle, K ^b   Gombert, F O ^a  

^a Polyphor Ltd   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Anti infectives; Anti virals; Antimicrobial peptides; CXCR4 inhibitor; Gram negative bacteria; Macrocyclic compounds; Protein epitope mimetics technology; Pseudomonas aeruginosa

Indexed keywords

ANTHELMINTIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BIPHENOMYCIN A; CAPREOMYCIN; CILUPREVIR; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ENOPEPTIN DERIVATIVE; IB 367; KATANOSIN A; LYSOBACTIN; MACROCYCLIC COMPOUND; MIKAMYCIN B; PLERIXAFOR; POLYMYXIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PRISTINAMYCIN; PROTEGRIN; RAMOPLANIN; STREPTOGRAMIN DERIVATIVE; THIOPEPTIDE ANTIBIOTIC AGENT; TUBERACTINOMYCIN; TYROCIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; WAP 8294 A2; WS 43708 A;

ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CARDIOTOXICITY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CYTOTOXICITY; DIARRHEA; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA; ANIMAL; CHEMICAL STRUCTURE; SYNTHESIS;

ANIMALS; ANTHELMINTICS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; HUMANS; MACROCYCLIC COMPOUNDS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 61949116417     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787002844     Document Type: Review

References (188)

1. Nathan, C. Antibiotics at the crossroads. Nature, 2004, 431, 899-902.
2. Frechette, R. In Ann. Rep. Med. Chem., Elsevier, 2007, pp. 349-64.
3. Von Nussbaum, F.; Brands, M.; Hinzen, B.; Weigand, S.; Häbich, D. Antibacterial natural products in medicinal chemistry-exodus or revival? Angew. Chem. Int. Ed. Engl., 2006, 45, 5072-129.
4. Wessjohann, L.A.; Ruijter, E.; Garcia-Rivera, D.; Brandt, W. What can a chemist learn from nature's macrocycles? A brief, conceptual view. Mol. Divers., 2005, 9, 171-86.
5. Newman, D.J.; Cragg, G.M.; Snader, K.M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 2003, 66, 1022-37.
6. Zhang, M.Q.; Wilkinson, B. Drug discovery beyond the 'rule-of-five'. Curr. Opin. Biotechnol., 2007, 18, 478-88.
7. Omura, S. Macrolide Antibiotics, Academic Press: San Diego, USA, 2002.
8. Jiang, L.; Moehle, K.; Dhanapal, B.; Obrecht, D.; Robinson, J.A. Combinatorial biomimetic chemistry: Parallel synthesis of a small library of ß-hairpin mimetics based on loop III from human platelet-derived growth factor B. Helv. Chem. Acta, 2000, 83, 3097-112.
9. Robinson, J.A.; DeMarco, S.J.; Gombert, F.O.; Moehle, K.; Obrecht, D. The design, structures and therapeutic potential of protein epitope mimetics. Drug Disc. Today, 2008, 13, 944-951.
10. DeMarco, S.J.; Henze, H.; Lederer, A.; Moehle, K.; Mukherjee, R.; Romagnoli, B.; Robinson, J.A.; Brianza, F.; Gombert, F.O.; Lociuro, S.; Ludin, C.; Vrijbloed, J.W.; Zumbrunn, J.; Obrecht, J.P.; Obrecht, D.; Brondani, V.; Hamy, F.; Klimkait, T. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg. Med. Chem., 2006, 14, 8396-404.
11. Shankaramma, S.C.; Athanassiou, Z.; Zerbe, O.; Moehle, K.; Mouton, C.; Bernardini, F.; Vrijbloed, J.W.; Obrecht, D.; Robinson, J.A. Macrocyclic hairpin mimetics of the cationic antimicrobial peptide protegrin I: A new family of broad-spectrum antibiotics. Chembiochem., 2002, 3, 1126-33.
12. Hopwood, D.; Levy, S.; Wenzel, R.P.; Georgopapadakou, N.; Baltz, R.H.; Bhavnani, S.; Cox, E. A call to arms. Nat. Rev. Drug Discov., 2007, 6, 8-12.
13. Projan, S.J.; Bradford, P.A. Late stage antibacterial drugs in the clinical pipeline. Curr. Opin. Microbiol., 2007, 10, 441-46.
14. Talbot, G.H.; Bradley, J.; Edwards, J.E., Jr.; Gilbert, D.; Scheld, M.; Bartlett, J.G. Bad bugs need drugs: An update on the development pipeline from the antimicrobial availability task force of the infectious diseases Society of America. Clin. Infect. Dis., 2006, 42, 657-68.
15. Falagas, M.E.; Kasiakou, S.K. Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit. Care, 2006, 10, R27.
16. Bagley, M.C.; Dale, J.W.; Merritt, E.A.; Xiong, X. Thiopeptide antibiotics. Chem. Rev., 2005, 105, 685-714.
17. Hughes, R.A.; Moody, C.J. From amino acids to heteroaromatics - thiopeptide antibiotics, nature's heterocyclic peptides. Angew. Chem. Int. Ed. Engl., 2007, 46, 7930-54.
18. Nicolaou, K.C.; Zak, M.; Rahimipour, S.; Estrada, A.A.; Lee, S.H.; O'Brate, A.; Giannakakou, P.; Ghadiri, M.R. Discovery of a biologically active thiostrepton fragment. J. Am. Chem. Soc., 2005, 127, 15042-44.
19. Harms, J.M.; Wilson, D.N.; Schluenzen, F.; Connell, S.R.; Stachelhaus, T.; Zaborowska, Z.; Spahn, C.M.; Fucini, P. Translational regulation via L11: Molecular switches on the ribosome turned on and off by thiostrepton and micrococcin. Mol. Cell, 2008, 30, 26-38.
20. Porse, B.T.; Leviev, I.; Mankin, A.S.; Garrett, R.A. The antibiotic thiostrepton inhibits a functional transition within protein L11 at the ribosomal GTPase centre. J. Mol. Biol., 1998, 276, 391-404.
21. Parmeggiani, A.; Krab, I.M.; Okamura, S.; Nielsen, R.C.; Nyborg, J.; Nissen, P. Structural basis of the action of pulvomycin and GE2270 A on elongation factor Tu. Biochemistry, 2006, 45, 6846-57.
22. Clough, J.; Chen, S.; Gordon, E.M.; Hackbarth, C.; Lam, S.; Trias, J.; White, R.J.; Candiani, G.; Donadio, S.; Romano, G.; Ciabatti, R.; Jacobs, J.W. Combinatorial modification of natural products: Synthesis and in vitro analysis of derivatives of thiazole peptide antibiotic GE2270 A: A-ring modifications. Bioorg. Med. Chem. Lett., 2003, 13, 3409-14.
23. Nicolaou, K.C.; Safina, B.S.; Zak, M.; Lee, S.H.; Nevalainen, M.; Bella, M.; Estrada, A.A.; Funke, C.; Zecri, F.J.; Bulat, S. Total synthesis of thiostrepton. Retrosynthetic analysis and construction of key building blocks. J. Am. Chem. Soc., 2005, 127, 11159-75
24. Hughes, R.A.; Thompson, S.P.; Alcaraz, L.; Moody, C.J. Total synthesis of the thiopeptide antibiotic amythiamicin D. J. Am. Chem. Soc., 2005, 127, 15644-51.
25. Delgado, O.; Muller, H.M.; Bach, T. Concise total synthesis of the thiazolyl peptide antibiotic GE2270 A. Chemistry., 2008, 14, 2322-39.
26. Nicolaou, K.C.; Dethe, D.H.; Leung, G.Y.; Zou, B.; Chen, D. Y. Total synthesis of thiopeptide antibiotics GE2270A, GE2270T, and GE2270C1. Chem. Asian J., 2008, 3, 413-29.
27. Campagne, J.M. Total Syntheses of Lysobactin (Katanosin B). Angew. Chem. Int. Ed. Engl., 2007, 46, 8548-52.
28. Bonner, D.P.; O'Sullivan, J.; Tanaka, S.K.; Clark, J.M.; Whitney, R.R. Lysobactin, a novel antibacterial agent produced by Lysobacter sp. II. Biological properties. J. Antibiot., 1988, 41, 1745-51.
29. O'Sullivan, J.; McCullough, J.E.; Tymiak, A.A.; Kirsch, D.R.; Trejo, W.H.; Principe, P.A. Lysobactin, a novel antibacterial agent produced by Lysobacter sp. I. Taxonomy, isolation and partial characterization. J. Antibiot., 1988, 41, 1740-44.
30. Shoji, J.; Hinoo, H.; Matsumoto, K.; Hattori, T.; Yoshida, T.; Matsuura, S.; Kondo, E. Isolation and characterization of katanosins A and B. J. Antibiot., 1988, 41, 713-18.
31. von Nussbaum, F.; Anlauf, S.; Benet-Buchholz, J.; Häbich, D.; Köbberling, J.; Musza, L.; Telser, J.; Rübsamen-Waigmann, H.; Brunner, N.A. Structure and total synthesis of lysobactin (katanosin B). Angew. Chem. Int. Ed. Engl., 2007, 46, 2039-42.
32. Breukink, E.; de Kruijff, B. Lipid II as a target for antibiotics. Nat. Rev. Drug Discov., 2006, 5, 321-32.
33. Maki, H.; Miura, K.; Yamano, Y. Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicr. Agents Chemoth., 2001, 45, 1823-27.
34. Tymiak, A.A.; McCormick, T.J.; Unger, S.E. Structure determination of lysobactin, a macrocyclic peptide lactone antibiotic. J. Org. Chem., 1989, 54, 1149-57.
35. Von Nussbaum, F.; Brunner, N.; Fürstner, C.; Endermann, R.; Ragot, J.; Telser, J.; Schroeder, W.; Anlauf, S.; Schumacher, A.; Hartmann, E. Cyclic nonapeptide amides. WO/2006/048156, 2006.
36. Benner, E.J.; Morthland, V. Methicillin-resistant Staphylococcus aureus. Antimicrobial susceptibility. New Engl. J. Med., 1967, 277, 678-80.
37. Khardori, N. Antibiotics - past, present, and future. Med. Clin. North Am., 2006, 90, 1049-76.
38. McAlpine, J.B.; Yagisawa, M. In Ann. Report. Med. Chem., Doherty, A.M. Ed.; Elsevier: Amsterdam, 2005; Vol. 40, pp. 301-21.
39. Van, B.F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr. Opin. Investig. Drugs, 2006, 7, 740-49.
40. Nicolaou, K.C.; Boddy, C.N.; Bräse, S.; Winssinger, N. Chemistry, biology, and medicine of the glycopeptide antibiotics. Angew. Chem. Int. Ed. Engl., 1999, 38, 2096-152.
41. Zhang, A.J.; Burgess, K. Total syntheses of vancomycin. Angew. Chem. Int. Ed. Engl., 1999, 38, 634-36.
42. Malabarba, A.; Ciabatti, R. Glycopeptide derivatives. Curr. Med. Chem., 2001, 8, 1759-73.
43. Mercier, R.C.; Hrebickova, L. Oritavancin: A new avenue for resistant gram-positive bacteria. Expert. Rev Anti. Infect. Ther., 2005, 3, 325-32.
44. Pace, J.L.; Judice, J.K. Telavancin (Theravance). Curr. Opin. Investig. Drugs, 2005, 6, 216-25.
45. Attwood, R.J.; LaPlante, K.L. Telavancin: A novel lipoglycopeptide antimicrobial agent. Am. J. Health Syst. Pharm., 2007, 64, 2335-48.
46. Bailey, J.; Summers, K.M. Dalbavancin: A new lipoglycopeptide antibiotic. Am. J. Health Syst. Pharm., 2008, 65, 599-610.
47. Poulakou, G.; Giamarellou, H. Oritavancin: A new promising agent in the treatment of infections due to Gram-positive pathogens. Expert. Opin. Investig. Drugs, 2008, 17, 225-43.
48. Dorr, M.B.; Jabes, D.; Cavaleri, M.; Dowell, J.; Mosconi, G.; Malabarba, A.; White, R.J.; Henkel, T.J. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J. Antimicrob. Chemother., 2005, 55 Suppl 2, ii25-ii30.
49. Miao, V.; Coeffet-Legal, M.F.; Brian, P.; Brost, R.; Penn, J.; Whiting, A.; Martin, S.; Ford, R.; Parr, I.; Bouchard, M.; Silva, C.J.; Wrigley, S.K.; Baltz, R.H. Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology, 2005, 151, 1507-23
50. Raja, A.; LaBonte, J.; Lebbos, J.; Kirkpatrick, P. Daptomycin. Nat. Revs. Drug Disc., 2003, 2, 943-44.
51. Kanafani, Z.A.; Corey, G.R. Daptomycin: A rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert. Rev. Anti. Infect. Ther., 2007, 5, 177-84.
52. Grunewald, J.; Sieber, S.A.; Mahlert, C.; Linne, U.; Marahiel, M.A. Synthesis and derivatization of daptomycin: A chemoenzymatic route to acidic lipopeptide antibiotics. J. Am. Chem. Soc., 2004, 126, 17025-31.
53. Nguyen, K.T.; Ritz, D.; Gu, J.-Q.; Alexander, D.; Chu, M.; Miao, V.; Brian, P.; Baltz, R.H. Combinatorial biosynthesis of novel antibiotics related to daptomycin. Proc. Natl. Acad. Sci. USA, 2006, 103, 17462-67.
54. Fulco, P.; Wenzel, R.P. Ramoplanin: A topical lipoglycodepsipeptide antibacterial agent. Exp. Rev. Anti. Infect. Ther., 2006, 4, 939-45.
55. Sarabia, F.; Chammaa, S.; Ruiz, A.S.; Ortiz, L.M.; Herrera, F.J. Chemistry and biology of cyclic depsipeptides of medicinal and biological interest. Curr. Med. Chem., 2004, 11, 1309-32.
56. Cavalleri, B.; Pagani, H.; Volpe, G.; Selva, E.; Parenti, F. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics. J. Antibiot., 1984, 37, 309-17.
57. Kurz, M.; Guba, W. 3D structure of ramoplanin: A potent inhibitor of bacterial cell wall synthesis. Biochemistry, 1996, 35, 12570-75.
58. Hu, Y.; Helm, J.S.; Chen, L.; Ye, X.Y.; Walker, S. Ramoplanin inhibits bacterial transglycosylases by binding as a dimer to lipid II. J. Am. Chem. Soc., 2003, 125, 8736-37.
59. Petersen, P.J.; Wang, T.Z.; Dushin, R.G.; Bradford, P.A. Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates. Antimicrobiotic Agents Chemother., 2004, 48, 739-46.
60. Ballard, C.E.; Yu, H.; Wang, B. Recent developments in depsipeptide research. Curr. Med. Chem., 2002, 9, 471-98.
61. Kato, A.; Nakaya, S.; Kokubo, N.; Aiba, Y.; Ohashi, Y.; Hirata, H.; Fujii, K.; Harada, K. A new anti-MRSA antibiotic complex, WAP-8294A. I. Taxonomy, isolation and biological activities. J. Antibiot., 1998, 51, 929-35.
62. Kato, A.; Nakaya, S.; Ohashi, Y.; Hirata, H.; Fujii, K.; Harada, K. WAP-8294A2, A Novel Anti-MRSA Antibiotic Produced by Lysobacter sp. J. Am. Chem. Soc., 1997, 119, 6680-81.
63. Bonfiglio, G.; Furneri, P.M. Novel streptogramin antibiotics. Expert. Opin. Investig. Drugs, 2001, 10, 185-98.
64. Zinser, S.H. Antibiotic use: Present and future. New Microbiol., 2008, 30, 321-25.
65. Dowzicky, M.; Nadler, H.L.; Feger, C.; Talbot, G.; Bompart, F.; Pease, M. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am. J. Med., 1998, 104, 34S-42S.
66. Tu, D.; Blaha, G.; Moore, P.B.; Steitz, T.A. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell, 2005, 121, 257-70.
67. Harms, J.M.; Schluenzen, F.; Fucini, P.; Bartels, H.; Yonath, A. Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol., 2004, 2, 4.
68. Ezaki, M.; Iwami, M.; Yamashita, M.; Hashimoto, S.; Komori, T.; Umehara, K.; Mine, Y.; Kohsaka, M.; Aoki, H.; Imanaka, H. Biphenomycins A and B, novel peptide antibiotics. I. Taxonomy, fermentation, isolation and characterization. J. Antibiot., 1985, 38, 1453-61
69. Martin, J.H.; Mitscher, L.A.; Shu, P.; Porter, J.N.; Bohonos, N.; DeVoe, S.E.; Patterson, E.L. LL-AF283-alpha and LL-AF283-beta, antibacterial antibiotics of unusual biological properties. Antimicrob. Agents Chemother., 1967, 7, 422-25.
70. Martin, D.E.; Shen, J.; Griener, J.; Raasch, R.; Patterson, J.H.; Cascio, W. Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide. J. Clin. Pharmacol., 1996, 36, 85-91.
71. Schmidt, U.; Meyer, V.; Leitenberger, A.; Lieberknecht, H.; Griesser, J. The synthesis of biphenomycin B. J. Chem. Soc. Chem. Commun., 1991, 275-77.
72. Lampe, T.; Adelt, I.; Beyer, D.; Brunner, N.; Endermann, R.; Ehlert, K.; Kroll, H.P.; Von Nussbaum, F.; Raddatz, S.; Rudolph, J.; Schiffer, G.; Schumacher, A.; Cancho-Grande, Y.; Michels, M.; Weigand, S. Antibacterial amide macrocycles. WO/2005/033129, 2005.
73. Finlay, A.C.; Hobby, G.L.; Hoschstein, F.; Lees, T.M.; Lenert, T.F.; Means, J.A.; P'An, S.Y.; Regna, P.P.; Routien, J.B.; Sobin, B.A.; Tate, K.B.; Kane, J.H. Viomycin a new antibiotic active against Mycobacteria. Am. Rev. Tuberc., 1951, 63, 1-3.
74. Bycroft, B.W.; Cameron, D.; Croft, L.R.; Hassanali-Walji, A.; Johnson, A.W.; Webb, T. Total structure of capreomycin IB, a tuberculostatic peptide antibiotic. Nature, 1971, 231, 301.
75. Herr Jr., E.B.; Henry, M.E.; Pittenger, G.E.; Higgens, C.E. Proc. Indiana Acad. Sci., 1960, 69, 134.
76. Herr Jr., E.B.; Redstone, M.O. Chemical and physical characterization of capreomycin. Ann. NY Acad. Sci., 1966, 135, 940-46.
77. Dirlam, J.P.; Belton, A.M.; Birsner, N.C.; Brooks, R.R.; Chang, S.P.; Chandrasekaran, R.Y.; Clancy, J.; Cronin, B.J.; Dirlam, B.P.; Finegan, S.M.; Froshauer, S.A.; Girard, A.E.; Hayashi, S.F.; Howe, R.J.; Kane, J.C.; Kamicker, B.J.; Kaufman, S.A.; Kolosko, N.L.; LeMay, M.A.; Linde, R.G.; Lyssikatos, J.P.; MacLelland, C.P.; Magee, T.V.; Massa, M.A.; Miller, S.A.; Minich, M.L.; Perry, D.A.; Petitpas, J.W.; Reese, C.P.; Seibel, S.B.; Su, W.G.; Sweeney, K.T.; Whipple, D.A.; Yang, B.V. Cyclic homopentapeptides 1. Analogs of tuberactinomycins and capreomycin with activity against vancomycin-resistant enterococci and Pasteurella. Bioorg. Med. Chem. Lett., 1997, 7, 1139-44.
78. Linde, R.G.; Birsner, N.C.; Chandrasekaran, R.Y.; Clancy, J.; Howe, R.J.; Lyssikatos, J.P.; MacLelland, C.P.; Magee, T.V.; Petitpas, J.W.; Rainville, J.P.; Su, W.G.; Vu, C.B.; Whipple, D.A. Cyclic homopentapeptides 3. Synthetic modifications to the capreomycins and tuberactinomycins: Compounds with activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Bioorg. Med. Chem. Lett., 1997, 7, 1149-52.
79. Lyssikatos, J.P.; Chang, S.P.; Dirlam, J.P.; Finegan, S.M.; Girard, A.E.; Hayashi, S.F.; Larson, D.P.; Lee, A.S.; Linde Ii, R.G.; McLelland, C.P.; Petipas, J.W.; Seibel, S.B.; Vu, C.B. Cyclic homopentapeptides 2. Synthetic modifications of viomycin. Bioorg. Med. Chem. Lett., 1997, 7, 1145-48.
80. Michel, K.H.; Kastner, R.E. A54556 antibiotics and process of production thereof. US patent 4,492,650, 1985.
81. Osada, H.; Yano, T.; Koshino, H.; Isono, K. Enopeptin A, a novel depsipeptide antibiotic with anti-bacteriophage activity. J. Antibiot., 1991, 44, 1463-66.
82. Schmidt, U.; Neumann, K.; Schumacher, A.; Weinbrenner, S. Synthesis of Enopeptin B from Streptomyces sp RK-1051. Angew. Chem. Int. Ed., 1997, 36, 1110-12.
83. Hinzen, B.; Raddatz, S.; Paulsen, H.; Lampe, T.; Schumacher, A.; Habich, D.; Hellwig, V.; Benet-Buchholz, J.; Endermann, R.; Labischinski, H.; Brötz-Oesterhelt, H. Medicinal Chemistry Optimization of Acyldepsipeptides of the Enopeptin Class Antibiotics. Chem. Med. Chem., 2006, 1, 689-93.
84. Brötz-Oesterhelt, H.; Beyer, D.; Kroll, H.P.; Endermann, R.; Ladel, C.; Schroeder, W.; Hinzen, B.; Raddatz, S.; Paulsen, H.; Hennenger, K.; Bandow, J.E.; Sahl, H.G.; Labschinski, H. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med., 2005, 11, 1082-87.
85. Young, J.J.; Jung, L.J.; Liu, W.T.; Ho, S.N.; Chang, L.R.; Tsai, Y.C.; Bhaskaran, R.; Yu, C. Solution conformation of enopeptin A, a depsipeptide antibiotic, using 2D NMR and restrained molecular dynamics studies. J. Antibiot., 1994, 47, 922-31.
86. Hinzen, B.; Raddatz, S.; Paulsen, H.; Lampe, T.; Schumacher, A.; Habich, D.; Hellwig, V.; et-Buchholz, J.; Endermann, R.; Labischinski, H.; Brotz-Oesterhelt, H. Medicinal chemistry optimization of acyldepsipeptides of the enopeptin class antibiotics. Chem. Med. Chem., 2006, 1, 689-93.
87. Hancock, R.E. Cationic antimicrobial peptides: Towards clinical applications. Exp. Opin. Invest. Drugs, 2000, 9, 1723-29.
88. Hancock, R.E.W.; Sahl, H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotech., 2006, 24, 1551-57.
89. Hancock, R.E.; Lehrer, R. Cationic peptides: A new source of antibiotics. Trends Biotechnol., 1998, 16, 82-88
90. O'Grady, F.; Greenwood D. In Antibiotic and Chemotherapy: Anti-infective agents and their use in therapy, 7th Edition, O'Grady, F.; Lambert, H.P.; Finch, R.G; Greenwood, D., Eds.; Churchill Livingstone Inc.: New York, 1997, pp. 336-43.
91. Tonge, A.P.; Murray-Rust, P.; Gibbons, W.A.; McLachlan, L.K. Determination of the major solution conformation of tyrocidine A, using molecular mechanics energy minimization and NMR-derived distance and torsion angle constraints. J. Comp. Chem., 1988, 9, 522-38.
92. Marques, M.A.; Citron, D.M.; Wang, C.C. Development of tyrocidine A analogues with improved antibacterial activity. Bioorg. Med. Chem., 2007, 15, 6667-77.
93. Kohli, R.M.; Walsh, C.T.; Burkart, M.D. Biomimetic synthesis and optimization of cyclic peptide antibiotics. Nature, 2002, 418, 658-61.
94. Lin, H.; Walsh, C.T. A chemoenzymatic approach to glycopeptide antibiotics. J. Am. Chem. Soc., 2004, 126, 13998-4003.
95. Xiao, Q.; Pei, D. High-throughput synthesis and screening of cyclic peptide antibiotics. J. Med. Chem., 2007, 50, 3132-37.
96. Koyama, Y.; Kurosasa, A.; Tsuchiya, A.; Takukuta, K. J. Antibiot., 1950, 3, 457-58.
97. Storm, D.R.; Rosenthal, K.S.; Swanson, P.E. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem., 1977, 46, 723-63.
98. Brown, J.M.; Dorman, D.C.; Roy, L.P. Acute renal failure due to overdosage of colistin. Med. J. Aust., 1970, 2, 923-24.
99. Koch-Weser, J.; Sidel, V.W.; Federman, E.B.; Kanarek, P.; Finer, D.C.; Eaton, A.E. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med., 1970, 72, 857-68.
100. Falagas, M.E.; Kasiakou, S.K. Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis., 2005, 40, 1333-41
101. Weinstein, J.; Afonso, A.; Moss, E., Jr.; Miller, G.H. Selective chemical modifications of polymyxin B. Bioorg. Med. Chem. Lett., 1998, 8, 3391-96.
102. Steinberg, D.A.; Hurst, M.A.; Fujii, C.A.; Kung, A.H.; Ho, J.F.; Cheng, F.C.; Loury, D.J.; Fiddes, J.C. Protegrin-1: A broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicr. Agents Chemother., 1997, 41, 1738-42.
103. Aumelas, A.; Mangoni, M.; Roumestand, C.; Chiche, L.; Despaux, E.; Grassy, G.; Calas, B.; Chavanieu, A. Synthesis and solution structure of the antimicrobial peptide protegrin-1. Eur. J. Biochem., 1996, 237, 575-83.
104. Fahrner, R.L.; Dieckmann, T.; Harwig, S.S.L.; Lehrer, R.I.; Eisenberg, D.; Feigon, J. Solution structure of protegrin-1, a broad-spectrum antimicrobial peptide from porcine leukocytes. Chem. Biol., 1996, 3, 543-50.
105. Roumestand, C.; Louis, V.; Aumelas, A.; Grassy, G.; Calas, B.; Chavanieu, A. Oligomerization of protegrin-1 in the presence of DPC micelles. A proton high-resolution NMR study. FEBS Lett., 1998, 421, 263-67.
106. Mani, R.; Tang, M.; Wu, X.; Buffy, J.J.; Waring, A.J.; Sherman, M.A.; Hong, M. Membrane-bound dimer structure of a beta-hairpin antimicrobial peptide from rotational-echo double-resonance solid-state NMR. Biochemistry, 2006, 45, 8341-49.
107. Tang, M.; Waring, A.J.; Lehrer, R.L.; Hong, M. Effects of guanidinium-phosphate hydrogen bonding on the membrane-bound structure and activity of an arginine-rich membrane peptide from solid-state NMR spectroscopy. Angew. Chem. Int. Ed., 2008, 47, 3202-05.
108. Payne, D.J.; Gwynn, M.N.; Holmes, D.J.; Pompliano, D.L. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat. Revs. Drug Disc., 2007, 6, 29-40.
109. De, C.E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov., 2007, 6, 1001-18.
110. Lamarre, D.; Anderson, P.C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bos, M.; Cameron, D.R.; Cartier, M.; Cordingley, M.G.; Faucher, A.M.; Goudreau, N.; Kawai, S.H.; Kukolj, G.; Lagace, L.; LaPlante, S.R.; Narjes, H.; Poupart, M.A.; Rancourt, J.; Sentjens, R.E.; St, G.R.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y.S.; Weldon, S.M.; Yong, C.L.; Llinas-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature, 2003, 426, 186-89.
111. He, Y.; King, M.S.; Kempf, D.J.; Lu, L.; Lim, H.B.; Krishnan, P.; Kati, W.; Middleton, T.; Molla, A. Relative replication capacity and selective advantage profiles of PI-resistant HCV NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob. Agents Chemother., 2008, 52, 1101-10.
112. Flisiak, R.; Dumont, J.M.; Crabbe, R. Cyclophilin inhibitors in hepatitis C viral infection. Expert. Opin. Invest. Drugs, 2007, 16, 1345-54.
113. Blanco, J.; Barretina, J.; Henson, G.; Bridger, G.; De, C.E.; Clotet, B.; Este, J.A. The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrob. Agents Chemother., 2000, 44, 51-56.
114. Zampella, A.; D'Orsi, R.; Sepe, V.; Casapullo, A.; Monti, M.C.; D'Auria, M.V. Concise synthesis of all stereoisomers of beta-methoxytyrosine and determination of the absolute configuration of the residue in callipeltin A. Org. Lett., 2005, 7, 3585-88.
115. Chen, H.C.; Chou, C.K.; Sun, C.M.; Yeh, S.F. Suppressive effects of destruxin B on hepatitis B virus surface antigen gene expression in human hepatoma cells. Antivir. Res., 1997, 34, 137-44.
116. Goudreau, N.; Llinas-Brunet, M. The therapeutic potential of NS3 protease inhibitors in HCV infection. Exp. Opin. Invest. Drugs, 2005, 14, 1129-44.
117. Llinas-Brunet, M.; Bailey, M.D.; Ghiro, E.; Gorys, V.; Halmos, T.; Poirier, M.; Rancourt, J.; Goudreau, N. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: Discovery of potent and specific tripeptide inhibitors. J. Med. Chem., 2004, 47, 6584-94.
118. Luban, J.; Bossolt, K.L.; Franke, E.K.; Kalpana, G.V.; Goff, S.P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell, 1993, 73, 1067-78.
119. Watashi, K.; Ishii, N.; Hijikata, M.; Inoue, D.; Murata, T.; Miyanari, Y.; Shimotohno, K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell, 2005, 19, 111-22.
120. Paeshuyse, J.; Kaul, A.; De, C.E.; Rosenwirth, B.; Dumont, J.M.; Scalfaro, P.; Bartenschlager, R.; Neyts, J. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology, 2006, 4 3, 761-70.
121. Kazmierski, W.M.; Gudmundsson, K.S.; Piscitelli, S.C. In Annual Reports in Medicinal Chemistry; Macor J.E., Ed.; Elsevier: Amsterdam, 2007; Vol. 42, pp. 301-20.
122. De Clercq, E. The bicyclam AMD3100 story. Nat. Rev. Drug Discov. 2003, 2, 581-87.
123. Hendrix, C.W.; Flexner, C.; Macfarland, R.T.; Giandomenico, C.; Fuchs, E.J.; Redpath, E.; Bridger, G.; Henson, G.W. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemoth., 2000, 44, 1667-73.
124. Zampella, A.; Randazzo, A.; Borbone, N.; Lucani, S.; Travisi, L.; Debitus, C.; D'Auria, M.V. Isolation of callipeltins A-C and of two new open-chain derivatives of callipeltin A from the marine sponge Latrunculia sp. A revision of the stereostructure of callipeltins. Tetrahedron Lett., 2002, 43, 6163-66.
125. Calimsiz, S.; Morales Ramos, A.I.; Lipton, M.A. Solid-phase synthesis and configurational reassigment of callipeltin E. Implications for the structures of callipeltins A and B. J. Org. Chem., 2006, 71, 6351-56.
126. D'Auria, M.V.; Zampella, A.; Palma, L.; Minale, L. Callipeltins B and C; bioactive peptides from a marine Lithistida sponge Callipelta sp. Tetrahedron, 1996, 52, 9589-96.
127. Tsunoo, A.; Kamijo, M. Non-cyclic AMP-dependent, positive inotropic cyclodepsipeptides with negative chronotropy. J. Pharmacol. Exp. Ther., 1999, 290, 1006-12.
128. Oku, N.; Krishnamoorthy, R.; Benson, A.G.; Ferguson, R.L.; Lipton, M.A.; Phillips, L.R.; Gustafson, K.R.; McMahon, J.B. Complete stereochemistry of neamphamide A and absolute configuration of the methoxytyrosine residue in papuamide B. J. Org. Chem., 2005, 70, 6842-47.
129. Di Santo, R. In Annual Reports in Medicinal Chemistry, Wood, A. Ed.; Elsevier: Amsterdam, 2006; Vol. 41, pp. 299-315.
130. Fostel, J.M.; Lartey, P.A. Emerging novel antifungal agents. Drug Discov. Today, 2000, 5, 25-32.
131. Chakrabarti, A. Microbiology of systemic fungal infections. J. Postgrad. Med., 2005, 51 Suppl 1, S16-S20.
132. Vicente, M.F.; Basilio, A.; Cabello, A.; Pelaez, F. Microbial natural products as a source of antifungals. Clin. Microbiol. Infect., 2003, 9, 15-32.
133. Cappelletty, D.; Eiselstein-McKitrick, K. The echinocandins. Pharmacotherapy, 2007, 27, 369-88.
134. Kasanah, N.; Hamann, M.T. Development of antibiotics and the future of marine microorganisms to stem the tide of antibiotic resistance. Curr. Opin. Invest. Drugs, 2004, 5, 827-37.
135. Mozzi, G.; Benelli, P.; Bruzzese, T.; Galmozzi, M.R.; Bonabello, A. The use of lipid emulsions for the iv administration of a new water soluble polyene antibiotic, SPK-843. J. Antimicrob. Chemother., 2002, 49, 321-25.
136. Gibbs, W.J.; Drew, R.H.; Perfect, J.R. Liposomal amphotericin B: clinical experience and perspectives. Expert. Rev. Anti. Infect. Ther., 2005, 3, 167-81.
137. Ostrosky-Zeichner, L.; Oude Lashof, A.M.; Kullberg, B.J.; Rex, J.H. Voriconazole salvage treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis., 2003, 22, 651-55.
138. Chandrasekar, P.H.; Ito, J.I. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis., 2005, 40 Suppl 6, S392-S400.
139. Baddour, L.M.; Perfect, J.R.; Ostrosky-Zeichner, L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin. Infect. Dis., 2005, 40 Suppl 6, S409-S13.
140. Von Benz, F.; Knusel, F.; Nuesch, J.; Treichler, H.; Voser, W.; Nyfeler, R.; Keller-Schierlein, W. Stoffwechselprodukte von Mikroorganismen 143. Mitteilung. Echinocandin B, ein neuartiges Polypeptid-Antibioticum aus Aspergillus nidulans var. echinulatus: Isolierung und Bausteine. Helv. Chim. Acta, 1974, 57, 2459-77.
141. Leonard, W.R.; Belyk, K.M.; Conion, D.A.; Bender, D.R.; DiMichele, L.M.; Liu, J.; Hughes, D.L. Synthesis of the Antifungal -1,3-Glucan Synthase Inhibitor CANCIDAS (Caspofungin Acetate) from Pneumocandin B0. J. Org. Chem., 2007, 72, 2335-43.
142. Kurtz, M.B.; Douglas, C.M. Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol., 1997, 35, 79-86
143. Bartizal, K.; Gill, C.J.; Abruzzo, G.K.; Flattery, A.M.; Kong, L.; Scott, P.M.; Smith, J.G.; Leighton, C.E.; Bouffard, A.; Dropinski, J.F.; Balkovec, J. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother., 1997, 41, 2326-32.
144. Ganesan, L.T.; Manavathu, E.K.; Cutright, J.L.; Alangaden, G.J.; Chandrasekar, P.H. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. Clin. Microbiol. Infect., 2004, 10, 961-66.
145. Takesako, K.; Ikai, K.; Haruna, F.; Endo, M.; Shimanaka, K.; Sono, E.; Nakamura, T.; Kato, I.; Yamaguchi, H. Aureobasidins, new antifungal antibiotics. Taxonomy, fermentation, isolation, and properties. J. Antibiot., 1991, 44, 919-24.
146. Kurome, T.; Inoue, T.; Takesako, K.; Kato, I. Syntheses of antifungal aureobasidin A analogs with alkyl chains for structure-activity relationship. J. Antibiot., 1998, 51, 359-67.
147. Ogawa, A.; Hashida-Okado, T.; Endo, M.; Yoshioka, H.; Tsuruo, T.; Takesako, K.; Kato, I. Role of ABC transporters in aureobasidin A resistance. Antimicrob. Agents Chemother., 1998, 42, 755-61.
148. Hanafi, M.; Shibata, K.; Ueki, M.; Taniguchi, M. UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. II. Structural elucidation. J. Antibiot., 1996, 49, 1226-31.
149. Ueki, M.; Abe, K.; Hanafi, M.; Shibata, K.; Tanaka, T.; Taniguchi, M. UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. I. Fermentation, isolation, and biological properties. J. Antibiot., 1996, 49, 639-43.
150. Ueki, M.; Kusumoto, A.; Hanafi, M.; Shibata, K.; Tanaka, T.; Taniguchi, M. UK-3A, a novel antifungal antibiotic from Streptomyces sp. 517-02: fermentation, isolation, structural elucidation and biological properties. J. Antibiot., 1997, 50, 551-55.
151. Takimoto, H.; Machida, K.; Ueki, M.; Tanaka, T.; Taniguchi, M. UK-2A, B, C and D, Novel Antifungal Antibiotics from Streptomyces sp. 517-02. IV. Comparative Studies of UK-2A with Antimycin A3 on Cytotoxic Activity and Reactive Oxygen Species Generation in LLC-PK1 Cells. J. Antibiot., 1999, 52, 480-84.
152. Maehr, H.; Liu, C.M.; Palleroni, N.J.; Smallheer, J.; Todaro, L.; Williams, T.H.; Blount, J.F. Microbial products. VIII. Azinothricin, a novel hexadepsipeptide antibiotic. J. Antibiot., 1986, 39, 17-25.
153. Smitka, T.A.; Deeter, J.B.; Hunt, A.H.; Mertz, F.P.; Ellis, R.M.; Boeck, L.D.; Yao, R.C. A83586C, a new depsipeptide antibiotic. J. Antibiot., 1988, 41, 726-33.
154. Harrison, L.; Teplow, D.B.; Rinaldi, M.; Strobel, G. Pseudomycins, a family of novel peptides from Pseudomonas syringae possessing broad-spectrum antifungal activity. J. Gen. Microbiol., 1991, 137, 2857-65.
155. Sasaki, T.; Takagi, M.; Yaguchi, T.; Miyadoh, S.; Okada, T.; Koyama, M. A new anthelmintic cyclodepsipeptide, PF1022A. J. Antibiot., 1992, 45, 692-97.
156. Conder, G.A.; Johnson, S.S.; Nowakowski, D.S.; Blake, T.E.; Dutton, F.E.; Nelson, S.J.; Thomas, E.M.; Davis, J.P.; Thompson, D.P. Anthelmintic profile of the cyclodepsipeptide PF1022A in in vitro and in vivo models. J. Antibiot., 1995, 48, 820-23.
157. Martin, R.J.; Robertson, A.P.; Bjorn, H. Target sites of anthelmintics. Parasitology, 1997, 114 Suppl, S111-S24.
158. Jeschke, P.; Harder, A.; von Samson-Himmelstjerna, G.; Etzel, W.; Gau, W.; Thielking, G.; Bonse, G. Synthesis of anthelmintically active N-methylated amidoxime analogues of the cyclic octadepsipeptide PF1022A. Pest. Manag. Sci., 2002, 58, 1205-15.
159. Zahner, H.; Taubert, A.; Harder, A.; von Samson-Himmelstjerna, G. Effects of Bay 44-4400, a new cyclodepsipeptide, on developing stages of filariae (Acanthocheilonema viteae, Brugia malayi, Litomosoides sigmodontis) in the rodent Mastomys coucha. Acta Trop., 2001, 80, 19-28.
160. Athanassiou, Z.; Dias, R.L.; Moehle, K.; Dobson, N.; Varani, G.; Robinson, J.A. Structural mimicry of retroviral tat proteins by constrained beta-hairpin peptidomimetics: Ligands with high affinity and selectivity for viral TAR RNA regulatory elements. J. Am. Chem. Soc., 2004, 126, 6906-13.
161. Athanassiou, Z.; Patora, K.; Dias, R.L.A.; Moehle, K.; Robinson, J.A.; Varani, G. Structure-guided peptidomimetic design leads to nanomolar beta-hairpin inhibitors of the Tat-TAR interaction of bovine immunodeficiency Virus. Biochemistry, 2007, 46, 741-51.
162. Leeper, T.C.; Athanassiou, Z.; Dias, R.L.A.; Robinson, J.A.; Varani, G. TAR RNA recognition by a cyclic peptidomimetic of Tat protein. Biochemistry, 2005, 44, 12362-72.
163. Descours, A.; Moehle, K.; Renard, A.; Robinson, J.A. A new family of beta-hairpin mimetics based on a trypsin inhibitor from sunflower seeds. Chembiochem, 2002, 3, 318-23.
164. Dias, R.L.; Fasan, R.; Moehle, K.; Renard, A.; Obrecht, D.; Robinson, J.A. Protein ligand design: From phage display to synthetic protein epitope mimetics in human antibody Fc-binding peptidomimetics. J. Am. Chem. Soc., 2006, 128, 2726-32.
165. Fasan, R.; Dias, R.L.; Moehle, K.; Zerbe, O.; Obrecht, D.; Mittl, P.R.; Grutter, M.G.; Robinson, J.A. Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction. Chembiochem, 2006, 7, 515-26.
166. Fasan, R.; Dias, R.L.; Moehle, K.; Zerbe, O.; Vrijbloed, J.W.; Obrecht, D.; Robinson, J.A. Using a beta-hairpin to mimic an alpha-helix: Cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction. Angew. Chem. Int. Ed. Engl., 2004, 43, 2109-12.
167. Favre, M.; Moehle, K.; Jiang, L.; Pfeiffer, B.; Robinson, J.A. Structural mimicry of canonical conformations in antibody hypervariable loops using cyclic peptides containing a heterochiral diproline template. J. Am. Chem. Soc., 1999, 121, 2679-85
168. Shankaramma, S.C.; Moehle, K.; James, S.; Vrijbloed, J.W.; Obrecht, D.; Robinson, J.A. A family of macrocyclic antibiotics with a mixed peptide-peptoid beta-hairpin backbone conformation. Chem. Commun. (Camb.), 2003, 1842-43.
169. Späth, J.; Stuart, F.; Jiang, L.; Robinson, J.A. Stabilization of a β-hairpin conformation in a cyclic peptide using the templating effect of a heterochiral diproline unit. Helv. Chim. Acta, 1998, 81, 1726-38.
170. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature, 2002, 415, 389-95.
171. Masuda, M.; Nakashima, H.; Ueda, T.; Naba, H.; Ikoma, R.; Otaka, A.; Terakawa, Y.; Tamamura, H.; Ibuka, T.; Murakami, T. A novel anti-HIV synthetic peptide, T-22 (Tyr5,12,Lys7-polyphemusin II). Biochem. Biophys. Res. Commun., 1992, 189, 845-50.
172. Miyata, T.; Tokunaga, F.; Yoneya, T.; Yoshikawa, K.; Iwanaga, S.; Niwa, M.; Takao, T.; Shimonishi, Y. Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity. J. Biochem., 1989, 106, 663-68.
173. Nakamura, T.; Furunaka, H.; Miyata, T.; Tokunaga, F.; Muta, T.; Iwanaga, S.; Niwa, M.; Takao, T.; Shimonishi, Y. Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab ( Tachypleus tridentatus). Isolation and chemical structure. J. Biol. Chem., 1988, 263, 16709-13.
174. Tang, Y.Q.; Yuan, J.; Osapay, G.; Osapay, K.; Tran, D.; Miller, C.J.; Ouellette, A.J.; Selsted, M.E. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science, 1999, 286, 498-502.
175. Brogden, K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol., 2005, 3, 238-50.
176. Robinson, J.A.; Shankaramma, S.C.; Jetter, P.; Kienzl, U.; Schwendener, R.A.; Vrijbloed, J.W.; Obrecht, D. Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. Bioorg. Med. Chem., 2005, 13, 2055-64.
177. Frecer, V. QSAR analysis of antimicrobial and haemolytic effects of cyclic cationic antimicrobial peptides derived from protegrin-1. Bioorgan. Med. Chem., 2006, 14, 6065-74.
178. Srinivas, N.; Moehle, K.; Abou-Hadeed, K.; Obrecht, D.; Robinson, J.A. Biaryl amino acid templates in place of D-Pro-L-Pro in cyclic β-hairpin cationic antimicrobial peptidomimetics. Org. Biomol. Chem., 2007, 5, 3100-05.
179. Chabot, D.J.; Broder, C.C. Substitutions in a homologous region of extracellular loop 2 of CXCR4 and CCR5 alter coreceptor activities for HIV-1 membrane fusion and virus entry. J. Biol. Chem., 2000, 275, 23774-82.
180. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996, 272, 872-77.
181. Nakashima, H.; Masuda, M.; Murakami, T.; Koyanagi, Y.; Matsumoto, A.; Fujii, N.; Yamamoto, N. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): A possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother., 1992, 36, 1249-55.
182. Tamamura, H.; Kuroda, M.; Masuda, M.; Otaka, A.; Funakoshi, S.; Nakashima, H.; Yamamoto, N.; Waki, M.; Matsumoto, A.; Lancelin, J.M. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance. Biochim. Biophys. Acta, 1993, 1163, 209-16.
183. Moncunill, G.; rmand-Ugon, M.; Clotet-Codina, I.; Pauls, E.; Ballana, E.; Llano, A.; Romagnoli, B.; Vrijbloed, J.W.; Gombert, F.O.; Clotet, B.; De Marco, S.; Este, J.A. Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026. Mol. Pharmacol., 2008, 73, 1264-73.
184. Schafer, M.; Schneider, T.R.; Sheldrake, G.M. Crystal structure of vancomycin. Structure, 1996, 4, 1509-15.
185. Ball, L.J.; Goult, C.M.; Donarski, J.A.; Micklefield, J.; Ramesh, V. NMR structure determination and calcium binding effects of lipopeptide antibiotic daptomycin. Org. Biomol. Chem., 2004, 2, 1872-78.
186. Norcia, L.J.L.; Silvia, A.M.; Dirlam, J.P.; Schnur, R.C.; Bergeron, J.M.; Retsema, J.A.; Hayashi, S.F. In vitro microbiological characterization of novel cyclic homopentapeptides, CP-101680 and CP-163,234 for animal health use. J. Antibiot. 1999, 52, 1007-16.
187. Pristovsek, P.; Kidric, J. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: An NMR and molecular modeling study. J. Med. Chem., 1999, 42, 4604-13.
188. Gao, X.; Wen, X.; Esser, L.; Quinn, B.; Yu, L.; Yu, C.-A.; Xia, D. Structural basis for the quinone reduction in the bc(1) complex: A comparative analysis of crystal structures of mitochondrial cytochrome bc(1) with bound substrate and inhibitors at the Q(i) site. Biochemistry, 2003, 42, 9067-80.